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Abstract
Background In a high proportion of patients with favor-
able outcome after aneurysmal subarachnoid hemorrhage
(aSAH), neuropsychological deficits, depression, anxiety,
and fatigue are responsible for the inability to return to
their regular premorbid life and pursue their professional
careers. These problems often remain unrecognized, as
no recommendations concerning a standardized compre-
Presentation at congresses: The recommendations have been submitted as
an abstract to the annual meeting of the Swiss Society of Neurosurgery, as
well as for the Vasospasm congress 2015.
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hensive assessment have yet found entry into clinical
routines.
Methods To establish a nationwide standard concerning a
comprehensive assessment after aSAH, representatives of
all neuropsychological and neurosurgical departments of
those eight Swiss centers treating acute aSAH have agreed
on a common protocol. In addition, a battery of question-
naires and neuropsychological tests was selected, optimally
suited to the deficits found most prevalent in aSAH pa-
tients that was available in different languages and
standardized.
Results We propose a baseline inpatient neuropsychological
screening using the Montreal Cognitive Assessment (MoCA)
between days 14 and 28 after aSAH. In an outpatient setting at
3 and 12 months after bleeding, we recommend a neuropsy-
chological examination, testing all relevant domains including
attention, speed of information processing, executive func-
tions, verbal and visual learning/memory, language, visuo-
perceptual abilities, and premorbid intelligence. In addition,
a detailed assessment capturing anxiety, depression, fatigue,
symptoms of frontal lobe affection, and quality of life should
be performed.
Conclusions This standardized neuropsychological assess-
ment will lead to a more comprehensive assessment of the
patient, facilitate the detection and subsequent treatment of
previously unrecognized but relevant impairments, and help
to determine the incidence, characteristics, modifiable risk
factors, and the clinical course of these impairments after
aSAH.
Keywords Aneurysmal subarachnoid hemorrhage .
Neuropsychological assessment . Cognitive deficits .
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Introduction
Some decades ago, neurosurgeons, neuroradiologists, and
neurointensive care physicians struggled to save the pure life
of patients who had suffered from aneurysmal arachnoid hem-
orrhage (aSAH). Meanwhile, outcomes have improved due to
less invasive aneurysm occlusion, newly introduced treatment
options, and evidence-based managing guidelines [40].
However, up to a third of all aSAH patients still die
as a consequence of severe brain damage in the pre-
hospital phase or delayed brain injury in the subacute
phase. On the other hand, however, a significant propor-
tion of patients with low- or high-grade aSAH respond
well to resuscitation and aggressive treatment and keep
or regain their functional independence.
In clinical practice, neurovascular surgeons frequently en-
counter patients who survive the aSAH and seem to be func-
tionally more or less independent, without any obvious neu-
rological or cognitive deficits. Traditionally, these patients are
assessed by means of rather imprecise neurological grading
scales such as the Glasgow Outcome Scale (GOS) or the mod-
ified Rankin Scale (mRS). Still, many of these patients need
weeks or months to regain their premorbid level, and resume
work, if at all. Also, a majority of patients with an aSAH have
to reduce their workload significantly, undergo professional
retraining to a less demanding occupation, or have problems
in relationships, family life, or leisure activities, indicating
post-hemorrhagic difficulties due to e.g., cognitive deficits,
depression, fatigue, or post-traumatic stress disorder [28, 47,
48, 56, 57, 68]. These facts clearly call for a more comprehen-
sive assessment of those patients. Accordingly, many studies
on this matter have revealed a strikingly high incidence of
neuropsychological deficits (NPD) in the population of aSAH
patients [1, 28]. These are, according to a body of literature,
determinants of functional independence, return to work, and
health-related quality of life (HRQoL) after aSAH [1, 11, 29,
37, 47, 48, 50, 56, 57]. These findings have prompted us to
reconsider the way aSAH patients are managed in Switzerland
today.
Objective
Our aim is to establish a nationwide uniform, standardized,
and validated neuropsychological assessment battery that is
optimally suited to assess the most prevalent deficits in aSAH
patients. This new set of tools must be available in different
languages (i.e., German, French, Italian, and English). It is the
goal of this recommendation to improve the management of
aSAH patients in Switzerland by using a pragmatic approach.
The specific aspects of these recommendations are (a) to offer
guidelines concerning a comprehensive neuropsychological
assessment for every aSAH patient, (b) to improve communi-
cation between neurosurgeons, neuropsychologists, rehabili-
tation units, and general practitioners, and (c) to expend
health-care resources responsibly by implementing a stan-
dardized assessment to avoiding redundant examinations by
multiple institutions.
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Methods
Aworkgroup consisting of representatives of the neurosurgical
departments and neuropsychological units of all eight Swiss
centers treating acute aSAH (in the following called Bthe
panel^) , namely the Kantonsspital Aarau (KSA),
Universitätsspital Basel (USB), Inselspital Bern (ISB),
Hôpitaux Universitaires de Genève (HUG), Centre Hospitalier
Universitaire Vaudois (CHUV, Lausanne), Ente Ospedaliero
Cantonale (EOC, Lugano), Kantonsspital St. Gallen (KSSG),
and the Universitätsspital Zürich (USZ) that had joined their
forces for the Swiss SOS study (www.swiss-sos.ch), were en-
gaged in several face-to-facemeetings and intense interpersonal
communication between 09/2012 and 01/2015.
Based on a literature review on neuropsychological testing
as well as HRQoL- and return to work outcomes after aSAH,
available tests and questionnaires were collected and selected
according to their sensitivity, validity, and utility in the popu-
lation of aSAH patients. Only well-standardized tests and,
from a more practical point of view, tests available in the three
major languages of Switzerland (German, French, and Italian)
were considered. Dissent was solved by personal discussion
between the members.
The panel agreed on a standardized approach (Fig. 1)
based on clear inclusion and exclusion criteria (Table 1)
concerning the neuropsychological assessment of aSAH
patients. Along with a comprehensive interview, the
neuropsychological assessment battery had to fulfill the
following criteria.
– Applicability in the clinical routine, i.e., considering both
the reasonability to the aSAH patient, as well as the work-
ing capacity of the neuropsychologists
– Choice of tests that are sensitive, standardized, and valid
including their availability in three official Swiss lan-
guages, i.e., German, French, and Italian as well as English
– Inclusion of tests/questionnaires that depict the areas of
impairment that are most commonly affected in aSAH
patients according to the current literature [1, 28, 29, 47,
48, 56, 57, 70, 81–83], namely (a) attention, (b) process-
ing speed, (c) executive functions, (d) verbal and visual
memory, (e) language, reading, writing, and calculation,
(f) visuo-perceptual abilities, (g) premorbid intelligence,
(h) depression, (i) anxiety, (j) fatigue, and (k) HRQoL
– Encumbers the health insurance system with reasonable
expenses and helps to prevent unnecessary expenses by
directing the patients into the right path as early as possible
Data of patients included in the Swiss SOS study is report-
ed in this work. Written informed consent was obtained from
all participants. Both local institutional review boards ap-
proved the study (Geneva: Autorisation générale Protocole
n° 11-233R (NAC 11-085R); St. Gallen: EKSG 12/016/1B).
Results
Our interdisciplinary recommendations concerning the imple-
mentation of a standardized assessment including neuropsy-
chological, functional, and HRQoL outcome into clinical rou-
tine have already been introduced at some of the centers in
Switzerland and will soon be established on a nationwide
basis. It is meant to serve the individual patient by detecting
potential cognitive deficits as well as psychosocial impairment
and rendering subsequent support and therapy possible. A
second goal of this initiative is the acquisition of the detailed
outcome data for scientific purposes within the framework of
the Swiss SOS study [66]. We encourage other physicians to
apply the same protocol in order to enable international com-
parison of standardized, detailed outcome measures and there-
by significantly foster clinical research.
Recommendation 1: Whom to test?
In general, all aSAH patients deserve to receive a comprehen-
sive assessment. However, in practice, certain factors need to
be taken into consideration leading to the exclusion criteria
outlined in Table 1. If a detailed neuropsychological testing at
one point is not possible due to functional impairments that
are a consequence of the aSAH itself, however, patients
should not be generally excluded from further testing. It is
well known that functional impairments often resolve over
time, so that those patients should be re-evaluated later.
Thus, if deficits are too severe on the first encounter on day
14 in the subacute phase, cognitive screening should be post-
poned until day 28 (Fig. 1). Irrespective of the degree of im-
pairment in the subacute phase, all aSAH patients should be
scheduled for a thorough examination at month 3 and 12 post-
hemorrhage (see below). At these time points, a screening will
help to determine if the comprehensive assessment can be
carried out. Lastly, detailed neuropsychological testing of pa-
tients with a formal education of less than 7 years is problem-
atic, as normative data is rarely available, and the results are
difficult to interpret. Optionally, the remaining assessment
tools (i.e., questionnaires and the Montreal Cognitive Assess-
ment, MoCA) may be performed in those patients.
Recommendation 2: When to test?
A scheme providing an overview of the time axis of the as-
sessments is presented in Fig. 1. In the acute phase of aSAH
(0–14 days post-aSAH), a neuropsychological assessment is
not reasonable or possible in a high percentage of patients, as
they may have a reduced state of vigilance and/or attention
span. Patients may still be comatose or have to undergo inten-
sive treatment despite being awake, including e.g., strict bed
rest and hypertensive treatment for cerebral vasospasm
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(CVS), resulting in the inability of the patient to undergo test-
ing at this time.
In the subacute phase (14–28 days post aSAH), we propose
using the Montreal Cognitive Assessment (MoCA) as a stan-
dard [49], which is a short, simple-to-perform screening tool
with a broad applicability and good validity for aSAH
[81–83]. Additional tests can be added to the baseline evalu-
ation at the discretion of the neuropsychologist to evaluate the
need for an in- or outpatient (neuropsychological) rehabilita-
tion program.We recommend administering theMoCA at day
14 post-aSAH, if possible. If the patient is unable to be tested
at day 14 (e.g., comatose, intubated, etc.), the MoCA can be
postponed day-by-day until day 28 post-aSAH. If the MoCA
cannot be administered until day 28, the patient will not be
tested at baseline. Most of these patients present with unfavor-
able outcome at hospital discharge, so that the physician can
usually decide for himself whether a transfer to an inpatient
rehabilitation (potential for recovery) or nursing home (no
potential for recovery) is necessary.
Three months after aSAH, a standardized interview
(Supplementary Table 1) and questionnaire-based evaluation
(Table 2) should be performed in every patient. In addition, the
MoCA should be repeated as a screening whether or not the
complete neuropsychological test battery can be applied (the
neuropsychologist should consider using parallel versions!). If
the MoCA score is ≥15 points, the test battery outlined in
Table 3 should be used to complete the comprehensive patient
evaluation. Patients not qualifying for the complete neuropsy-
chological examination at 3 months should, however, be re-
assessed 12 months post-aSAH. If the full neuropsychological
assessment is to be performed but patients are unable to do the
whole examination due to fatigue for example, some subtests
can be left out (at the discretion of the neuropsychologist) or
the assessment can be dispensed to two or more examination
dates. The examination at three months after aSAH is helpful
to evaluate return to work, or the working capacity in those
patients that have already restarted their professional lives.
Twelve months after aSAH, a second comprehensive out-
patient neuropsychological assessment (using the same meth-
od as described for the 3-month examination, including the
MoCA with a cut-off ≥15 points) should be performed in
every patient in order to estimate the presence and magnitude
of cognitive deficits, anxiety, depression, fatigue, behavioral
problems, and measure HRQoL. This visit is important in
order to assess the natural course of symptoms and deficits
or measure the efficacy of the applied therapy. In addition, this
examination helps to determine if specific therapy has to be
applied or continued, respectively.
Recommendation 3: How to test?
The following recommendations only apply to the follow-up
examinations at 3 and 12 months post-aSAH, as in the sub-
acute phase only the MoCA is performed (see above). The
Fig. 1 Scheme of the Swiss standardized assessment after aSAH.MoCA
Montreal Cognitive Assessment. * Testing should be performed on day
14 after aSAH, if possible. If not possible (e.g., patient still on respirator,
comatose, not safe to perform the testing for medical reasons), theMoCA
can be performed any day until day 28 after aSAH. If needed for the
decision of whether or not the patient needs an inpatient rehabilitation
program, the neuropsychologist can add specific tests at his discretion
Table 1 Recommended criteria of whether or not to perform a detailed
neuropsychological testing as part of a standardized outcome assessment
Inclusion criteria:
- Patient's age ≥18 years
Exclusion criteria:
- Education <7 years
- Impaired vision (defined as not being able to read the tests/
instructions even by aid of magnifying glasses)
- Impaired hearing (defined as not being able to follow a
conversation despite hearing aids)
- Insufficient language skills before aSAH (aphasic deficit as
consequence of aSAH is not an exclusion criterion)
- Unable to complete the assessment in German, French, Italian or English
- Impaired vigilance (defined as patients not responding to any
oral or visual communication)
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examination basically consists of three parts: (1) the interview,
(2) the subjective questionnaire-based evaluation, and (3) the
detailed neuropsychological assessment. It is important to
note that part (1) and (2) should be applied to every patient,
while not every patient qualifies for part (3). The complete
examination comprising all three parts should take approxi-
mately 2.5 h. Depending on the patients’ condition, a split of
the assessment should be considered.
Part (1): Baseline interview, including working status
and important life events
The assessment should begin with a structured patient inter-
view, where important patient characteristics are captured. The-
se should include: age, gender, handedness (right/left/both),
native language and language of examination, developmental-
or learning disabilities (No/Yes, Type?), previous CNS comor-
bidities (e.g., head injuries, epilepsy, stroke, depression, anxi-
ety), current medication, the consumption of cigarettes (number
per day), alcohol (drinks per day), or further drugs. To evaluate
the premorbid situation, the education in years and highest ed-
ucational level (e.g., university degree, doctorate, apprentice-
ship, etc.) must be assessed. To estimate the impact of aSAH
on the occupational career, both types of occupation before and
after aSAH according to the International Standard Classifica-
tion of Jobs (ISCO-88 COM) [75], the workload in percent
(before and after aSAH), as well as the last day of work
before- and the date of work resumption after aSAH should
be recorded [50]. To cope with the social impact of the disease,
we suggest inquiring about the family situations (e.g., marital
status) before and after aSAH. Before any neuropsychological
examination, the patient should be asked about self-pertained
cognitive symptoms before and after aSAH and whether a neu-
ropsychological examination had ever been performed before
the aSAH. A sample of our structured interview sheet can be
downloaded online from Supplementary Table 1.
Part (2): Questionnaires for anxiety, depression, fatigue,
behavioral abnormalities, and HRQoL
Questionnaires outlined in Table 2, collecting information on
anxiety, depression, fatigue, behavioral abnormalities as
Table 2 Selection of questionnaires proposed at 3 and 12 months post-
aSAH to collect information on anxiety, depression, fatigue, symptoms of
frontal lobe affection, and health-related quality of life.
- Hospital Anxiety and Depression Scale (HADS) [9, 56, 57, 76]
- Multidimensional Assessment of Fatigue (MAF) [37]
- Frontal Systems Behavior Scale (FrSBe) [41]
- Short-Form 12 (SF-12, including the Mental Component Scale (MCS)
and Physical Component Scale (PCS), the subscales of Physical
Functioning, Role-Physical, Bodily Pain, General Health, Vitality,
Social Functioning, Role-Emotional, Mental Health) [34, 74]
- Euro-Qol (EQ5D) [62]
Table 3 Recommended test
battery for a comprehensive
neuropsychological assessment 3
and 12 months after aneurysmal
subarachnoid hemorrhage
Domain Test/subtest
Cognitive screening - MoCA [81–83]
Attention - TAP 2.3, using the subtests alertness; divided attention; Go/NoGo
(1 out of 2); neglect (92 trials with switching letters) [35, 84]
- Verbal [12, 80] and visual [32] span - forward
Executive functions - Color-Word Interference Test (Victoria version) [7, 14, 20, 59, 60]
- Verbal fluencies (semantic and phonemic) [3, 15, 20, 38, 59]
- Design fluency (five-points test) [12, 20, 61]
- Cognitive flexibility (TMT B) [35, 59, 69]
- Problem-solving (SLP) [46]
Cognitive speed - TMTA [35, 59, 69]
Memory - Verbal learning and memory (AVLGT) [18, 55, 58]
- Nonverbal memory (RO-CFT– delayed recall) [1, 2, 20, 54]
- Verbal [12, 80] and visual working memory [32]
Visual-perceptual abilities - RO-CFT – copy [1, 2, 20, 54]
Language - Token test [1, 5, 36, 39]
- Reading, writing, number processing and calculation
(cursory examination)
Premorbid intelligence - Similarities [7, 12, 80]
Eye–hand coordination and motor speed - Grooved Pegboard Test [12, 14, 20, 63]
AVLGT Auditiv-verbaler Lern- und Gedächtnistest (as adaptation of the Rey Auditory Verbal Learning Tests
(RAVLT)), MoCA Montreal Cognitive Assessment, RO-CFT Rey-Osterrieth Complex Figure Test, SLP Stan-
dardized Link's Probe, TAP Computerized Test of Attentional Performance, TMT Trail Making Test
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probable symptoms of frontal lobe affection, and HRQoL are
an essential part of the neuropsychological assessment.
Part (3): Neuropsychological test battery
The detailed neuropsychological testing is reserved for
those patients that fulfill none of the exclusion criteria
outlined in Table 1. After re-administering the MoCA at
the beginning of the examination, one should refrain
from further detailed neuropsychological testing of pa-
tients scoring <15 points (reason outlined above). All
patients scoring ≥15 points on the MoCA, however,
qualify for a more detailed assessment using the test
battery proposed in Table 3. The following domains
are considered to be most important in aSAH patients
and are thus covered by the test battery: attention, ex-
ecutive functions, processing speed, memory, visuo-
perceptual and constructional abilities, as well as lan-
guage [1]. As mentioned, parts of the test battery may
be omitted or divided and performed on two or
more separate occasions if the patient is unable to per-
form the complete assessment in one session (e.g., lim-
ited span of attention, fatigue, aphasia). For the second
examination (at 12 months), parallel test versions should
be used whenever possible to prevent bias due to prac-
tice effects [64].
To conclude the assessment, observations made during the
neuropsychological examination should be documented as
proposed in Supplementary Table 2.
Discussion
We have undertaken efforts to develop and establish a nation-
wide standard that offers guidelines for a comprehensive as-
sessment of aSAH patients including neuropsychological,
psychosocial, and HRQoL implications of the disease. This
proposed standard has been implemented in some of the Swiss
neurovascular departments already, and is going to be adopted
by the remaining departments in the near future. With this
step, we hope to accurately diagnose the presence and magni-
tude of NPD, anxiety, depression, fatigue, and behavioral
problems in the individual patient.
A detailed assessment identifying the characteristics and
magnitude of the patient’s individual deficits helps to initialize
a specific therapy as early as possible and thereby maximize
the chance of recovery. Detection of these impairments is cru-
cial, as they are known to have a high incidence and impact on
the subjects’ well-being, the HRQoL and ability to work after
aSAH [11, 53, 78]. Also, the early identification of deficits
may help both the patient and his/her relatives to understand
the reason for possible difficulties in the psychosocial, famil-
iar, recreational and occupational re-integration, absorb future
complications, and be helpful in estimating the patient’s short-
and long-term working capacity. As such, a recent study dem-
onstrated that the neuropsychological outcome 12 months af-
ter aSAH could predict the ability to work even 10 years after
the assessment [78]. Since aSAH patients are generally much
younger than patients experiencing ischemic stroke for exam-
ple, the significance of this estimation and its impact on our
society becomes obvious. A detailed assessment is not possi-
ble in every patient, largely depending on his/her individual
clinical condition. As such, we have introduced the MoCA as
a screening tool (with the cut-off ≥15 points) to decide wheth-
er or not the comprehensive test battery can be applied at 3 and
12 months post-aSAH. This approach both avoids bothering
severely impaired patients and saves health care resources.
There are no previous studies defining a similar cut-off, but
it has been our experience in a pilot project on n=61 patients
that a extensive assessment is not possible in patients scoring
<15 points on the MoCA. In the subacute phase (14–28 days
post-aSAH) 48.2% of patients scored <15 points in the Mo-
CA, with the rate dropping to 25.8% and about 10% at 3 and
12 months post-aSAH. These numbers are in accordance with
previous literature [81–83] and indicate that the battery can be
applied to most of the surviving patients. Those that do not
qualify for a more detailed assessment should be considered
cognitively impaired and benefit from adequate support
(ergotherapy, specialized cognitive training). However, further
detailed testing of these patients using a 2.5-3 h face-to-face
interview is impossible and little meaningful at this time.
Standardizing the way aSAH patients are assessed in a
nationwide manner is a unique chance to study the incidence,
evolution, and risk factors for psychosocial impairments. As
such, we intend to record the results of the assessment in all
patients that agree to participate in the prospective multicentre
Swiss SOS study (www.swiss-sos.ch) [66]. By using the
structures of this already well-established network, we can
correlate psychosocial impairments to specific aspects of the
disease and its treatment and profit from this massive gain of
information not only from a scientific perspective, but also by
means of an improved assistance of the individual patient.
Identifying risk factors (especially modifiable risk factors)
for neuropsychological outcome after aSAH is essential to
facilitate their future prevention. As these are only beginning
to be determined [70], there is a great need for further progress
in clinical research. Only recently was it reported that charac-
teristics of NPD after aSAH differ from those of other types of
intracranial hemorrhage, as being more pronounced, but also
more reversible [10]. This is good news, as impairment seems
to be modifiable, again stressing the importance of its detec-
tion and subsequent therapy [70].
Until today, however, neuropsychological outcome after
aSAH is not always assessed, and is especially underreported
in scientific publications on aSAH. A recent analysis demon-
strated the paradox between a high incidence of NPD on the
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one hand, and an extremely low frequency of their standard-
ized assessment and scientific research in this area on the
other hand [71]. In addition, the current assessment of NPD
shows a great variability in published clinical series, and is
often subject to profound selection bias. The need to obtain
a general overview of neuropsychological outcome of
aSAH patients remains largely unmet. Reasons for this
are the missing neuropsychological infrastructure in
some countries, and the challenge of such an endeavor
with neurosurgeons and neuropsychologists of multiple
centers having to cooperate.
Medical care in Switzerland is generally highly developed,
and complex diseases such as aSAH are treated using the best
standards of care. All aSAH patients surviving the initial hem-
orrhage and being admitted to a hospital in Switzerland as
well as Liechtenstein and some neighboring regions of Italy,
France, Austria, and Germany, are transferred to one of the
above-mentioned centers for subsequent treatment. Owing to
geographical and epidemiological features, and the complex-
ity of the disease and its treatment, it has been decided in the
context of the BHochspezialisierte Medizin^ (HSM; highly
specialized medicine) discussion that aSAH should only be
treated at the eight tertiary neurovascular centers listed above
that cooperate tightly within the framework of the Swiss SOS
study (members are listed in the author list as well as in the
Appendix) [66]. Especially for a complex and relatively infre-
quent disease such as aSAH, standardized care, a focused
medical supply and both quality assessment and control as
well as scientific collaborations on a national level are war-
ranted. In Switzerland, the local circumstances render the im-
plementation of the proposed standard possible.
Limitations
The choice of tests and questionnaires that are depicted in
Tables 2 and 3 constitute a compromise of experiences with
aSAH patients, the availability of the tests in multiple lan-
guages, existence of normative data, alternate forms, as well
as their reproducibility, cost-effectiveness, and meaningful-
ness for patient and scientific evaluation. Of note, besides
the core test battery presented here, additional tests may be
added to evaluate more specific deficits related to specific
localization of the aSAH or its consequences (e.g., ruptured
aneurysm of the anterior communicating artery with a frontal
intracerebral hematoma—tests for social cognition; cerebral
vasospasm of the right middle cerebral artery—mental rota-
tion test). Still, the effect of fatigue in a significant percentage
of patients should not be underestimated and the assessment
kept as short as possible. From a scientific point of view, a
further complete testing 60 months after aSAH would be of
great interest to gain more insights into the clinical course of
the psychosocial evolution of our patients. However, as this
will be of little value to the clinical decision-making of the
individual patient, the long-term testing cannot be included in
this standard, which was primarily developed from a clinical
point of view to improve patient care.
The fact that a pragmatic approach was chosen over a sys-
tematic evidence-based method (Delphi method) might be
considered as a limitation. The agreement on this test battery
was arrived at an internal discussion of the advantages and
drawbacks of available tests, under the special consideration
of previous literature. Personal experience of the panel mem-
bers with this patient population supported the decision-mak-
ing, which is why our proposed standard is not strictly scien-
tific or evidence-based. Still, almost every test included in the
battery proposed here has been demonstrated to be sensitive,
valid, and utile in prior works on aSAH [4, 6, 8–11, 13, 14, 16,
17, 19–31, 33–37, 42–45, 47, 48, 50–53, 55, 56, 59, 62, 64,
65, 67, 70–74, 77–79, 81–83]. Establishing a standard is a big
challenge for a single department and even more so for a
whole nation with multiple language areas. By using a prag-
matic approach though, we have been able to define a reason-
able standard that might be adopted by further departments or
countries in order enable international comparison of the re-
sults. Future works of this group will aim at reporting results
using this battery that will help to estimate the burden of
aSAH in an unselected nationwide patient population. On-
going review of these results will help to optimize and possi-
bly shorten this current standard in the future to enhance broad
applicability, especially important for areas with fewer
resources.
Conclusions
We have developed a nationwide standard for a comprehensive
assessment of patients after aneurysmal subarachnoid hemor-
rhage that includes neuropsychological, psychosocial, and
HRQoL-aspects of the disease. This standard will be imple-
mented in all Swiss neurovascular departments treating acute
aSAH and aims to accurately diagnose the presence and mag-
nitude of neuropsychological deficits, as well as anxiety, de-
pression, fatigue, and HRQoL in the individual patient in order
to render subsequent treatment as early as possible. Scientific
analysis of these detailed outcomes will help to understand the
burden of this disease on patients and society, and enable fas-
cinating insights into the pathophysiology of aSAH.
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